Global Solid Tumor Drug Market Size, Share and Trends Analysis Report, By Type (Dostarlimab-gxly, Entrectinib, Jemperli (Dostarlimab-gxly), Keytruda (Pembrolizumab), Larotrectinib Sulfate, Pembrolizumab, Rozlytrek (Entrectinib), Vitrakvi (Larotrectinib Sulfate) and Other), By Application (Benign (Non-Cancerous) and Malignant (Cancerous)) Forecast Period (2022-2028)

The global solid tumor drug market is anticipated to grow at a CAGR of 12.2% during the forecast period (2022-2028). Solid tumors are abnormal masses of tissue that don’t contain any cysts or liquid areas. There are two sorts of tumors: benign (non-cancerous) and malignant (cancerous) (cancerous). Lymphomas, carcinomas, sarcomas, and melanomas are examples of these tumors. Radiotherapy, chemotherapy, and/or surgery are used to treat the majority of solid tumors. Increased demand for highly effective chemotherapeutic treatments, as well as exposure to risk factors such as alcohol consumption and obesity, are driving the global solid tumor drugs market. However, developments in treatment strategies, such as targeted and combination therapy for breast cancer, such as Kadcyla and Herceptin, give market growth potential.
Furthermore, due to their low cost and resemblance to the original substance, the emerging trend of biosimilars is contributing to the growth of the solid tumors treatment market. Herceptin, MabThera, Avastin, and Erbitux are only a few of the biologics available for the treatment of solid tumors. The ability of biosimilars to overcome the constraints of generic pharmaceuticals in the treatment of solid tumors is predicted to drive the market for solid tumor treatments forward.
Solid tumor medicines are used to treat cancer in oncology. Oncology offers a wide range of medications that can be taken orally or via injection, depending on the type of treatment required. Docetaxel is the most commonly utilized medicine; it belongs to the Taxanes class of drugs and aids in chemotherapy-related procedures. It also aids in the treatment of breast, ovarian, and prostate cancers, and due to the high rate of cancer treatment acceptance and expanded R&D to produce new medications, North America is likely to dominate the global market. The United States is the largest region in North America, with one of the largest pools of cancer patients and increasing R&D spending to find novel therapeutic therapies for solid tumor treatment.
Some major players in the market include AstraZeneca Group Companies., GlaxoSmithKline PLC, Celgene Corporation, Abbott Laboratories, Pfizer Inc, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in July 2019 GlaxoSmithKline PLC reported that the company has received encouraging results from Phase 3 of its PRIMA research. This is a ZEJULA study that is placebo-controlled, double-blind, and randomized. After platinum-based chemo, it is used as maintenance therapy for patients with ovarian cancer in the first line. The study concluded with a significant statistical improvement in the development of ovarian cancer treatment in women, independent of their biomarker status.

The market number available for – 2021-2028
Base year- 2021
Forecast period- 2022-2028

Segment Covered-
By Type
By Application

Regions Covered-
North America
Europe
Asia-Pacific
Rest of the World

Top Major Key Players:
AstraZeneca Group Companies., GlaxoSmithKline PLC., Celgene Corporation, Abbott Laboratories, Pfizer Inc, among others.

Key questions addressed by the report
What is the market growth rate?
Which segment and region dominate the market in the base year?
Which segment and region will project the fastest growth in the market?
How has COVID-19 impacted the market?
Deviation from the pre-COVID-19 forecast
Most affected region and segment
Who is the leader in the market?
How players are addressing challenges to sustain growth?
Where is the investment opportunity?

Global Solid Tumor Drug Market Report by Segment
By Type
Dostarlimab-gxly
Entrectinib
Jemperli (Dostarlimab-gxly)
Keytruda (Pembrolizumab)
Larotrectinib Sulfate
Pembrolizumab
Vitrakvi (Larotrectinib Sulfate)
Rozlytrek (Entrectinib)
Other

By Application
Benign (Non-Cancerous)
Malignant (Cancerous)